Skip to main navigation
Skip to search
Skip to main content
The Capital Region of Denmark's Research Portal Home
Dansk
English
Search content at The Capital Region of Denmark's Research Portal
Home
Hospitals/Departments
Researchers
Research output
Activities
Prizes
Avacopan for the Treatment of ANCA-Associated Vasculitis
David R W Jayne
, Peter A Merkel
, Thomas J Schall
, Pirow Bekker
, ADVOCATE Study Group
,
Wladimir Szpirt
(Member of author group)
Department of Kidney and Hormone Diseases
920
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Avacopan for the Treatment of ANCA-Associated Vasculitis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
100%
Avacopan
100%
Prednisone
66%
Remission
44%
Non-inferiority
33%
Sustained Remission
33%
Rituximab
22%
Birmingham Vasculitis Activity Score
22%
Cyclophosphamide
22%
Second Primary
22%
95% Confidence Interval
22%
Disease Activity
11%
Randomized Controlled Trial
11%
Clinical Effect
11%
Twice Daily
11%
High-score
11%
Serious Adverse Events
11%
Vasculitis
11%
Safety Impact
11%
Glucocorticoid Use
11%
C5a Receptor
11%
Oral Prednisone
11%
Receptor Inhibitors
11%
Pharmacology, Toxicology and Pharmaceutical Science
ANCA Associated Vasculitis
100%
Avacopan
100%
Remission
77%
Prednisone
77%
Vasculitis
33%
Rituximab
22%
Cyclophosphamide
22%
Disease Activity
11%
Adverse Event
11%
Randomized Controlled Trial
11%
Glucocorticoid
11%
Azathioprine
11%
Complement Component C5a Receptor
11%
Medicine and Dentistry
ANCA Associated Vasculitis
100%
Avacopan
100%
Prednisone
77%
Vasculitis
33%
Rituximab
22%
Cyclophosphamide
22%
Oral
22%
Disease Activity
11%
Randomized Controlled Trial
11%
Glucocorticoid
11%
Azathioprine
11%
Complement Component C5a Receptor
11%
Adverse Event
11%